Report cover image

Venture Capital Investment Trends In Pharma - Q4 2024

Publisher GlobalData
Published Jan 15, 2025
Length 21 Pages
SKU # GBDT19997596

Description

Venture Capital Investment Trends In Pharma - Q4 2024

Summary

This report analyzes the venture capital (VC) investment activity in Q4 2024 in the Pharma sector.

The global pharma sector in Q4 2024 witnessed investments worth $6.3 billion, a decline of 0.1% compared to Q3 2024. In terms of investment volume, there was a rise of 6.2% to 171 VC investments in Q4 2024. Oncology was the top therapy area with 74 deals by 203 investors.

Scope
  • This report provides an overview of VC investment activity globally in Q4 2024 in the Pharma sector involving biopharmaceutical drug companies.
  • It identifies key trends, and the most notable deals announced in Q4 2024 in the Pharma sector.
Reasons to Buy
  • Companies that strategically invest in venture funding position themselves for success, while those that fail to adapt risk falling behind.
  • This report provides an overview of global VC investment trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.

Table of Contents

21 Pages
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharma Venture Capital Activity in Q4 2024
3 Global VC Investment Trends in Pharma
4 Global Quarterly Funding Activity in Pharma
5 Notable Deals in Pharma
6 Global Mega Investments Trends in Pharma
7 Mega Investments Quarterly Funding Activity in Pharma
8 Global Investment Activity in Pharma by Deal Size
9 Global Investment Activity in Pharma by Deal Stages
10 Deal Activity in Pharma: Top Deal Stage Type Analysis
11 Pharma Regional Comparison - Q4 2024
12 Pharma Regional Investment Activity in Pharma by Value and Volume
13 Pharma Investment Review by Top 10 Countries
14 Top 10 Therapy Area Investment Review
15 Top Pharma Investors by Value in Q4 2024
16 Further Information
16.1 Methodology
17 Contact Us

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us